Mineral Metabolism Management in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan: Baseline Data from the MBD-5D | Zendy

Masafumi Fukagawa | Zendy; Hirotaka Komaba | Zendy; Yoshihiro Ônishi | Zendy; Shunichi Fukuhara | Zendy; Tadao Akizawa | Zendy; Kiyoshi Kurokawa | Zendy

Open Access

Mineral Metabolism Management in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan: Baseline Data from the MBD-5D

Author(s) -

Masafumi Fukagawa,

Hirotaka Komaba,

Yoshihiro Ônishi,

Shunichi Fukuhara,

Tadao Akizawa,

Kiyoshi Kurokawa

Publication year - 2011

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000327654

Subject(s) - medicine , secondary hyperparathyroidism , hemodialysis , hyperphosphatemia , parathyroidectomy , parathyroid hormone , hyperparathyroidism , dialysis , vitamin d and neurology , prospective cohort study , bone remodeling , calcium , bone mineral , calcium metabolism , chronic kidney disease mineral and bone disorder , endocrinology , urology , osteoporosis

The Mineral and Bone Disorder Outcomes Study for Japanese CKD Stage 5D Patients (MBD-5D) is a multicenter, prospective observational study of hemodialysis patients with secondary hyperparathyroidism (SHPT) in Japan, where the national guideline recommends targets for serum calcium (8.4-10.0 mg/dl), phosphorus (3.5-6.0 mg/dl), and intact parathyroid hormone (PTH) (60-180 pg/ml).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research